Medivation, Astellas report hormone-naïve prostate cancer data

Medivation Inc. (NASDAQ:MDVN) and Astellas Pharma Inc. (Tokyo:4503) said once-daily oral Xtandi enzalutamide met the primary endpoint in an open-label Phase II trial in 67 patients with hormone-naïve prostate cancer. Specifically, 93% of patients receiving Xtandi had a prostate-specific antigen (PSA) response -- defined as achieving a reduction from baseline in PSA level of 80% or greater -- at week 25. Medivation did not disclose the threshold needed to meet the endpoint. The median reduction in PSA level from baseline to week 25 was 99.6%. Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando. ...